Advertisement
Canada markets closed
  • S&P/TSX

    22,465.37
    +165.54 (+0.74%)
     
  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     
  • DOW

    40,003.59
    +134.21 (+0.34%)
     
  • CAD/USD

    0.7348
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    80.00
    +0.77 (+0.97%)
     
  • Bitcoin CAD

    91,127.57
    +143.12 (+0.16%)
     
  • CMC Crypto 200

    1,364.84
    -9.00 (-0.66%)
     
  • GOLD FUTURES

    2,419.80
    +34.30 (+1.44%)
     
  • RUSSELL 2000

    2,095.72
    -0.53 (-0.03%)
     
  • 10-Yr Bond

    4.4200
    +0.0430 (+0.98%)
     
  • NASDAQ

    16,685.97
    -12.35 (-0.07%)
     
  • VOLATILITY

    11.99
    -0.43 (-3.46%)
     
  • FTSE

    8,420.26
    -18.39 (-0.22%)
     
  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     
  • CAD/EUR

    0.6755
    -0.0001 (-0.01%)
     

SOPHiA GENETICS SA (NASDAQ:SOPH) surges 23%; individual investors who own 44% shares profited along with institutions

Key Insights

  • The considerable ownership by individual investors in SOPHiA GENETICS indicates that they collectively have a greater say in management and business strategy

  • The top 12 shareholders own 51% of the company

  • Institutions own 34% of SOPHiA GENETICS

To get a sense of who is truly in control of SOPHiA GENETICS SA (NASDAQ:SOPH), it is important to understand the ownership structure of the business. We can see that individual investors own the lion's share in the company with 44% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

While individual investors were the group that reaped the most benefits after last week’s 23% price gain, institutions also received a 34% cut.

ADVERTISEMENT

Let's delve deeper into each type of owner of SOPHiA GENETICS, beginning with the chart below.

See our latest analysis for SOPHiA GENETICS

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About SOPHiA GENETICS?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that SOPHiA GENETICS does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see SOPHiA GENETICS' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in SOPHiA GENETICS. Alychlo NV is currently the company's largest shareholder with 11% of shares outstanding. With 11% and 5.2% of the shares outstanding respectively, Generation Investment Management LLP and Balderton Capital (UK) LLP are the second and third largest shareholders. Furthermore, CEO Jurgi Camblong is the owner of 3.4% of the company's shares.

A closer look at our ownership figures suggests that the top 12 shareholders have a combined ownership of 51% implying that no single shareholder has a majority.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of SOPHiA GENETICS

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Shareholders would probably be interested to learn that insiders own shares in SOPHiA GENETICS SA. As individuals, the insiders collectively own US$14m worth of the US$286m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public-- including retail investors -- own 44% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With an ownership of 16%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 2 warning signs for SOPHiA GENETICS (1 is a bit unpleasant) that you should be aware of.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here